Fear acquisition and extinction mechanisms in relation to treatment outcome: a study in patients with anxiety disorders

Fear acquisition and extinction mechanisms in relation to treatment outcome: a study in patients with anxiety disorders - Fear acquisition & extinction mechanisms in relation to treatment outcome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39222

Enrollment

310

Registered

2011-09-09

Start date

2011-10-24

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorder

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: a. Patients with a lifetime diagnosis of the following disorders as a primary diagnosis: Panic disorder with or without agoraphobia, social anxiety disorder, specific phobia, generalized anxiety disorder, post-traumatic stress disorder and obsessive compulsive disorder. b. Males and females between 18 and 65 years old. c. Command of the Dutch language (i.e. ability to understand procedures and questionnaires). d. Normal or corrected normal vision.;The inclusion criteria for the healthy controls participating in conditioning task 1 are the same as described above, with the exception of criterium a.

Exclusion criteria

Exclusion criteria: a. Current comorbid severe psychiatric disorder in the past 6 months: i.e. severe major depressive disorder (BDI * 30), bipolar disorder, psychotic disorder. b. Lifetime history of substance dependence, or substance abuse within the last three months. c. Mental retardation (IQ

Design outcomes

Primary

Measure	Time frame
Primary endpoint measures of change indices are: State Trait Anxiety Inventory (state subscale) and Disorder specific ratings. Physiological (skin conductance response and electromyograhy) and self-reported (Visual analogue scales) measures are used to measure speed of fear acquisition, fear extinction and context learning. Various polymorphisms will be genotyped: serotonine (5HTTLPR, 5-HTR1A), dopamine (COMT Val158Met, DAT), cannabinoïd (CB1 rs2180619 en CB1 rs1049353) and glutamergic polymorfisms (SLC1A1/EAAC1 rs3780412, rs301430). Promising newly detected polymorphisms available through the literature will be tested as well.	—

Measure

Time frame

Primary endpoint measures of change indices are: State Trait Anxiety Inventory (state subscale) and Disorder specific ratings. Physiological (skin conductance response and electromyograhy) and self-reported (Visual analogue scales) measures are used to measure speed of fear acquisition, fear extinction and context learning. Various polymorphisms will be genotyped: serotonine (5HTTLPR, 5-HTR1A), dopamine (COMT Val158Met, DAT), cannabinoïd (CB1 rs2180619 en CB1 rs1049353) and glutamergic polymorfisms (SLC1A1/EAAC1 rs3780412, rs301430). Promising newly detected polymorphisms available through the literature will be tested as well.

—

Secondary

Measure	Time frame
Secondary objectives: several questionnaires and neuropsychological tests (see section 3.8 and 4.4 of the research protocol) were added to be able to control for possible modulating effects on fear conditioning, such as: depresion, memory function and life-events.	—

Countries

Netherlands

Outcome results